Research Article

Different Numbers of Long-Pulse 1064-nm Nd-YAG Laser Treatments for Onychomycosis: A Pilot Study

Rui-na Zhang,1 Feng-lin Zhuo,1 Dong-kun Wang,2 Li-zhi Ma,3 Jun-ying Zhao,1 and Lin-feng Li1

1Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2Department of Dermatology, Beijing Evercare Jianxiang Hospital, China
3Department of Dermatology, Chengdu Second People’s Hospital, China

Correspondence should be addressed to Jun-ying Zhao; zjy63014411@aliyun.com and Lin-feng Li; zoonli@sina.com

Received 30 April 2019; Revised 25 July 2019; Accepted 1 August 2019; Published 20 January 2020

Academic Editor: Xin Ming

Copyright © 2020 Rui-na Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To examine the benefits of different numbers of 1064-nm Nd-YAG laser treatments in patients with onychomycosis. Methods. This was a pilot study of patients with onychomycosis who were divided into three groups: four treatment sessions (group A), eight sessions (group B), and 12 sessions (group C). Only infected nails of degrees II–III (Scoring Clinical Index for Onychomycosis) were included. Treatment was given once a week using a long-pulse Nd-YAG 1064-nm laser. Patients were followed at 8, 16, and 24 weeks after the first treatment. Side effects were recorded.

Results. Treatments were completed for 442 nails in 102 patients. The efficacy rates at 8, 16, and 24 weeks were 35.5%, 38.7%, and 37.4% for group A; 31.4%, 41.7%, and 44.0% for group B; and 27.7%, 50.0%, and 55.4% for group C, respectively. There was a significant difference in the efficacy rate at 24 weeks (P = 0.016) between groups A and C, but not for groups A vs. B, or for groups B vs. C. No difference in the efficacy rate at 8 or 16 weeks was observed among the three groups. In all three groups, the efficacy was better for degree II nails than for degree III nails (all P < 0.05). No side effects occurred.

Conclusions. The 1064-nm Nd-YAG laser had clinical benefits against onychomycosis. Higher numbers of treatments provided better long-term (24-week) benefits, but had no impact on the short-term outcomes. The efficacy of laser treatment on degree II onychomycosis was better than for degree III.

1. Introduction

Onychomycosis is a persistent fungal infection of the nail bed and plate and is most commonly (85–90%) caused by dermatophytes such as *Trichophyton rubrum* [1, 2]. The worldwide incidence of onychomycosis is approximately 3–5% [3, 4] and increases with age [5]. Besides age, the risk factors are male gender, athletes, diabetes, peripheral vascular diseases, and HIV infection [1, 6]. Patients with onychomycosis may experience significant psychosocial problems because of the appearance of the nail, particularly when fingernails are involved [7].

The treatment of onychomycosis is challenging because the infection is embedded within the nail. Common antifungal drugs for external use or oral administration used for the treatment of onychomycosis include fluconazole, itraconazole, and terbinafine [1, 2, 6], but topical antifungal agents barely penetrate the nail plate and do not achieve local therapeutic concentrations, and systemic oral antifungal medications are not applicable for some patients with abnormal liver function or low immune function [8–10]. Therefore, a new treatment approach is needed.

Laser irradiation is an optional modality for treating onychomycosis. The possible indications of laser therapy include resistance to or low efficacy of topical antifungals, relapsing disease, and interactions and adverse events of systemic antifungals [11]. The lasers used for onychomycosis primarily include the carbon dioxide (CO2), 870-nm + 930-nm, and Nd-YAG 1064-nm lasers. The CO2 laser, which was the earliest method, can directly gasify and degrade tissues, killing the fungi [12]. Fractional CO2 laser combined with a topical antifungal agent showed good clinical efficacy for treating onychomycosis and it was suggested that combination therapy had a higher efficacy for treating onychomycosis than did fractional CO2 laser alone [13–15]. On the other hand, the CO2 laser is no longer used because of pain and
trauma. The 870-nm + 930-nm laser is a dual-wavelength near-infrared ray, and involves a thermal effect on fungal metabolism for onychomycosis treatment [16]. A previous study showed that the long-pulse neodymium-doped yttrium aluminum garnet (Nd-YAG) laser at a wavelength of 1064 nm (Beijing Shiji Guangtong Biotechnology Co., Ltd.) used for the treatment of 154 infected nails in 33 patients could cure 52% of the nails [17]. Many studies have confirmed that the 1064-nm Nd-YAG laser is effective against onychomycosis [11, 18–20]. The advantages of this laser include long wavelength, high energy, simple operation, strong penetrability, and no mutagenesis effect on cell DNA [18].

The most optimal number of treatments with the 1064-nm Nd-YAG laser for onychomycosis remains to be validated. Therefore, the aim of the present study was to examine the benefits of different numbers of 1064-nm Nd-YAG laser treatments in patients with onychomycosis. In order to ensure the comparability among groups and to compare the efficacy of different degrees of severity of onychomycosis with the same number of treatment sessions, we used the Scoring Clinical Index of Onychomycosis (SCIO Index) and only included infected nails of degrees II and III.

2. Methods

2.1. Participants. This was a pilot study of patients with onychomycosis who sought treatments between 2012 and 2015. The study was approved by the ethics committee of our institution and was registered with the Chinese Clinical Trial Registry (ChiCTR-ONC-17012746). All patients signed the informed consent form before participation.

The inclusion criteria were: (1) 18–65 years of age; (2) typical onychomycosis-related symptoms; (3) tested positive on direct microscopy examination; and (4) SCIO index of 6–12, consistent with degrees II–III. Topical antifungal agents were prohibited for 1 month prior to participation, and systemic antifungal agents for 6 months.

The exclusion criteria were: (1) patient dropped out or changed the treatment regimen or follow-up plan; (2) received other antifungal therapy or agents affecting the outcome during the study; (3) showed continuous or semi-continuous nail discoloration (for example, abnormal nail pigmentation caused by the use of topical antifungal therapy such as Castellani solution, nail-coloring dyes or polishes containing magnesium and iron, or occupational exposure to colorants or bitumen, regardless of the therapeutic or cosmetic purpose); (4) used photosensitivity-inducing medications within 6 months; (5) pregnant, (6) subungual hematoma or nevoid formation; or (7) other concomitant onychopathic-induced diseases such as nail-plate psoriasis, lichen planus, or atopic dermatitis. Those who dropped out from the study because of side effects were analyzed for side effects, and those in group C received 12 sessions.

2.2. Grouping and SCIO Index. The patients were randomly divided into three groups: four treatment sessions (group A), eight sessions (group B), and 12 sessions (group C).

Clinical classification, length of involvement, and degree of hyperkeratosis are the three indicators used to determine the severity of onychomycosis, and are directly related to treatment efficacy and number of sessions. Another important factor influencing efficacy is the growth rate of the nail, which mainly depends on age and location of the infected nail. Based on the SCIO index proposed by Sergeev [21] and Hu et al. [22], we semi-quantified and calculated the above five factors, which were divided into three levels and expressed by corresponding score (Table 1). The severity of the infected nails was divided into five degrees: degree I: SCIO < 6, degree II: 6 ≤ SCIO < 9, degree III: 9 ≤ SCIO < 12, degree IV: 12 ≤ SCIO < 15, and degree V: SCIO ≥ 15. Only nails of degrees II–III were included in this study.

2.3. Treatment. Treatment was given using a long-pulse Nd-YAG 1064-nm laser (Beijing Shiji Guangtong Biotechnology Co., Ltd.) using the following parameters: 240–348 J/cm², 3-mm spot size, 30-ms pulse duration, and 1-Hz frequency. The laser energy was adjusted based on the thickness of the nail plate. Thicker nails required higher energy. All infected nails in each patient were fully covered for 2 minutes by an incrementally moving laser beam in a spiral pattern, followed by a 2-minute pause, for three cycles. The treatment was performed at 1-week intervals. Patients in group A received four treatment sessions, those in group B received 8 sessions, and those in group C received 12 sessions.

2.4. Clinical Effect Assessment. All patients were followed up at 8, 16, and 24 weeks from the first day of treatment. The nails were analyzed and classified into four grades according to a classification modified from Lim et al. [13], as follows: “complete response or cure” (the nail appears fully normal from the proximal nail fold to involved nail), “significant response” (>60% normal-appearing nail compared with the area of the initially infected nail), “moderate response” (20–60% normal-appearing nail), and “no response” (<20% normal-appearing nail). The clinical efficacy rate was defined as the total percentage of nails with complete response and significant response. Side effects were recorded.

2.5. Patient Satisfaction. A satisfaction survey was conducted at the end of the study. The satisfaction was classified as: “very satisfied,” “satisfied,” “slightly satisfied,” or “not satisfied.”

### Table 1: Simplified scoring clinical index of onychomycosis.

| Variables                        | Scoring |
|----------------------------------|---------|
| Clinical classification          | WSO     |
| Length of involvement            | 1/3     |
| Degree of hyperkeratosis         | <1 mm   |
| Age of patients (years)          | 15–24   |
| Location of infected nail        | 2–4 fingernails |

WSO: white superficial onychomycosis; DLSO: distal lateral subnail onychomycosis; PSO: proximal subnail onychomycosis; TDO: total dystrophy onychomycosis.
2.6. Statistical Analysis. SPSS 22.0 (IBM, Armonk, NY, USA) was used for statistical analysis. Continuous variables are presented as mean ± standard deviation, and were analyzed using a one-way analysis of variance (ANOVA) with Tukey’s post hoc test. Categorical variables were presented as frequencies (percentage), and were analyzed using Fisher’s exact test. Post-hoc \( P < 0.0167 \) (Bonferroni correction, 0.05/3) was considered statistically different. The McNemar test was used to analyze the variables. Univariable and multivariable logistic regression analyses were performed to analyze the factors associated with efficacy. \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. Patients’ Characteristics. In group A, seven patients were lost to follow-up and 33 patients were included in the analysis, for a total of 155 nails. In group B, one patient was lost to follow-up and 39 patients were included in the analysis, for a total of 175 nails. In group C, ten patients were lost to follow-up and 30 patients were included in the analysis, for a total of 112 nails. Hence, 442 nails were included in the analysis.

The patients (34 males and 68 females) were 18–65 years of age. Table 2 presents the characteristics of the patients. There were more nails with <1 mm thickness in group B compared to other groups.

![Table 2: Patients’ characteristics.](image1)

| Variable                        | Group A (N = 33) | Group B (N = 39) | Group C (N = 30) | \( P \)  |
|---------------------------------|------------------|------------------|------------------|--------|
| Age (years)                     | 50.40 ± 12.5     | 47.00 ± 10.89    | 49.03 ± 9.96     | 0.308  |
| Duration of disease (years)     | 2.73 ± 1.22      | 2.39 ± 1.09      | 2.80 ± 1.51      | 0.338  |
| Gender, n (%)                   |                  |                  |                  | 0.949  |
| Male                            | 11 (33.3%)       | 13 (33.3%)       | 11 (36.7%)       |        |
| Female                          | 22 (66.7%)       | 26 (66.7%)       | 19 (63.3%)       |        |
| Total number of infected nails, n | 155              | 175              | 112              |        |
| Nail thickness (mm)             |                  |                  |                  | 0.008  |
| <1                              | 123 (79.4%)      | 159 (90.9%)\(^a\) | 92 (82.1%)\(^b\) |        |
| 1–2                             | 32 (20.6%)       | 16 (9.1%)\(^a\)  | 20 (17.9%)\(^b\) |        |
| Mean laser energy (J/cm²)       | 292.05 ± 13.83   | 283.14 ± 12.96\(^a\) | 289.77 ± 18.13 <0.001 |        |
| Location of infected nails, n (%)|                  |                  |                  | 0.014  |
| Fingernail                      | 17 (11.0%)       | 39 (22.3%)\(^a\) | 15 (13.4%)       |        |
| Toenail                         | 138 (89.0%)      | 136 (77.7%)\(^a\) | 97 (86.6%)       |        |
| Severity of infected nails, n (%)|                  |                  |                  | 0.908  |
| II                              | 75 (48.4%)       | 88 (50.3%)       | 57 (50.9%)       |        |
| III                             | 80 (51.6%)       | 87 (49.7%)       | 55 (49.1%)       |        |
| Clinical type of onychomycosis, n (%)|                  |                  |                  | 0.002  |
| DLSO                            | 108 (69.7%)      | 103 (58.9%)\(^b\) | 79 (70.5%)\(^a,b\) |        |
| WSO                             | 20 (12.9%)       | 26 (14.9%)\(^a\) | 3 (2.7%)\(^b\)  |        |
| PSO                             | 9 (5.8%)         | 6 (3.4%)\(^a\)  | 3 (2.7%)\(^b\)  |        |
| TDO                             | 18 (11.6%)       | 40 (22.9%)\(^a\) | 27 (24.1%)\(^a,b\)|        |

Group A: four sessions; Group B: eight sessions; Group C: 12 sessions. DLSO: distal lateral subnail onychomycosis; WSO: white superficial onychomycosis; PSO: proximal subnail onychomycosis; TDO: total dystrophy onychomycosis. \(^a\) \( P < 0.05 \), vs. group A; \(^b\) \( P < 0.05 \), vs. group B.

![Figure 1: Images before and after four treatment sessions for fingernail onychomycosis.](image2)
with the two other groups ($P = 0.008$). The patients in group B had more infected nails on the hands, and took less laser energy compared with group A ($P < 0.05$). The clinical types were also different among the three groups ($P = 0.002$). There were no differences among the three groups regarding severity ($P = 0.908$).

3.2. Clinical Effect. The clinical efficacy rates at 8, 16, and 24 weeks were 35.5%, 38.7%, and 37.4% for group A; 31.4%, 41.7%, and 44.0% for group B; and 27.7%, 50.0%, and 55.4% for group C, respectively (Table 3). More nails achieved recovery in group C at week 24 compared with group A ($P = 0.016$), but there were no differences between groups A and B, and between groups B and C. No difference in the efficacy rate at 8 or 16 weeks was observed among the three groups. In terms of severity (Table 4), the effective rate of nails with degree II disease was higher than that of nails with degree III at 8, 16, and 24 weeks in all three groups (all $P < 0.01$). Figures 1–4 present some typical cases.

Multivariable logistic regression analysis for efficacy at 24 weeks supported that group C could achieve a better efficacy (odds ratio [OR] = 2.589, 95% confidence interval [CI]: 1.342–4.994, $P = 0.005$), while degree III was a risk factor (OR = 0.107, 95%CI: 0.052–0.219, $P < 0.001$) (Table 5). In addition, age and nail thickness were independently associated with efficacy.

3.3. Satisfaction. In group A, four patients were very satisfied (12.1%), six were satisfied (18.2%), 16 were slightly satisfied (48.5%), and seven were dissatisfied (21.2%). In group B, eight patients were very satisfied (20.5%), 19 were satisfied (48.7%), seven were slightly satisfied (18.0%), and five were dissatisfied (12.8%). In group C, 10 patients were very satisfied (30.3%), five were satisfied (16.7%), 10 slightly were satisfied (30.3%), and five were dissatisfied (16.7%) (Table 6). Satisfaction was higher for group B compared with group A ($P = 0.025$), without difference between groups A and C ($P = 0.240$), and between groups B and C ($P = 0.065$).

3.4. Safety. No side effects were experienced by the 102 patients.

4. Discussion

The 1064-nm long-pulse Nd:YAG laser can be used to treat onychomycosis, but previous studies had small sample sizes and did not examine the impact of the number of treatments on the outcomes. In our study, we enrolled more subjects (102 patients with 442 effected nails) and included different numbers of treatment. We found that efficacy at
The response rates in this study were lower than those of oral drugs, which show cure rates of 76% for terbinafine, 59–63% for itraconazole, and 48% for fluconazole [1, 2, 6]. The possible reasons could be that the laser is most effective only during heat stimulation. When heat stimulation is interrupted, the fungi gradually grow again, interrupting clinical improvements and the efficacy rate or even leading to relapse. Antifungal agents such as terbinafine and itraconazole have high affinity to keratin, resulting in higher concentrations in the nails than in other body compartments. These agents can remain in the nails for 6–9 months after drug discontinuation [23]. The combination of drugs with the 1064-nm Nd-YAG laser should be explored [22]. Indeed, the mechanism of action of the laser is different from that of the drugs. The long-pulse Nd-YAG 1064-nm laser is characterized by a long wavelength, and the light energy penetrates the nail plate and reaches the nail bed. Chromophores in the walls of fungal cells can absorb this light energy and transform it into heat to damage the cell wall, resulting in fungal apoptosis [24, 25]. The laser also increases the temperature (to approximately 40°C) of the nail plate at the treatment site [16]. The fungi are damaged by repeated heat stimulation and the fungal mitochondria produce excess reactive oxygen species that overwhelm the protective capacity of the fungal cells, resulting in cell/fungal apoptosis and even death. The main advantage of antifungal agents is the maintenance of the effect even after the end of treatment. On the other hand, systemic drugs are sometimes contraindicated in some patients (e.g., those with liver dysfunction), while topical drugs are associated with a compliance issue [26]. Lasers could be used as an alternative in those cases and in patients who do not want to take medicine. In addition, combination treatments (laser and drugs) should be explored in the future.

Regarding the satisfaction survey, only four (12.1%) out of 33 people were very satisfied and six (18.2%) were satisfied. 24 weeks was significantly in group C vs. group A, but not between groups A and B, or between groups B and C, as supported by the multivariable analysis. There were no differences among the three groups at 8 and 16 weeks. The results suggest that higher numbers of treatments provided better long-term (24-week) benefits, but the number of treatments had no impact on the short-term outcomes (8 and 16 weeks). In this study, we used the SCIO for evaluating the severity of onychomycosis. The SCIO index was first proposed by Sergeev et al. [21] and subsequently simplified by Hu et al. [22]. We found that the efficacy rate was negatively correlated with the SCIO index. The efficacy was higher in nails of degree II (SCIO 6–8) than in degree III nails (SCIO 9–11) at 8, 16, and 24 weeks and in all three groups (all \( P < 0.05 \)). Hence, we concluded that the long-pulse 1064-nm Nd-YAG laser is more suitable for the treatment of degree II than for degree III onychomycosis. More severely infected nails (degree III) may need a combination of oral drugs or other treatments to improve the efficacy rate of the laser. The SCIO index may have a role in planning laser treatment for onychomycosis.

Regarding recurrence, the numbers of nails with recurrence in groups A and B were 11 (7.1%) and 16 (9.1%) at week 24, respectively, compared with two (1.8%) effectuated nails in group C. It was presumed that the fungi might have been partially killed or inhibited after laser irradiation, but that their reproductive capacity was gradually restored with time. Therefore, some infected nails that had improved early in the study returned to baseline when treatment ended. Second, the longer the treatment, the lower the recurrence rate. According to the present study, Group C was the most effective, with a rate of 55.4% at 24 weeks. Therefore, it may be hypothesized that the number of treatments should be extended as far as possible and, if necessary, treatments should be given until the infected nail is completely replaced by the new nail. A previous study with the CO2 laser showed no recurrence at 3 months [13], but the observation period was shorter than in the present study (12 vs. 24 weeks). Using the Q-switched Nd-YAG 1064-nm/532-nm laser, Kalokasidis et al. [5] showed a cure rate of 95.4% at 3 months. Wanitphakdeedecha et al. [19] showed cure rates of 63.5%, 57.7%, and 51.9% at 1, 3, and 6 months, indicating that recurrence rates were higher than in the present study. Of course, differences among treatment protocols might be responsible, at least in part, for the discrepancies observed among studies.

The possible reasons could be that the laser is most effective only during heat stimulation. When heat stimulation is interrupted, the fungi gradually grow again, interrupting clinical improvements and the efficacy rate or even leading to relapse. Antifungal agents such as terbinafine and itraconazole have high affinity to keratin, resulting in higher concentrations in the nails than in other body compartments. These agents can remain in the nails for 6–9 months after drug discontinuation [23]. The combination of drugs with the 1064-nm Nd-YAG laser should be explored [22]. Indeed, the mechanism of action of the laser is different from that of the drugs. The long-pulse Nd-YAG 1064-nm laser is characterized by a long wavelength, and the light energy penetrates the nail plate and reaches the nail bed. Chromophores in the walls of fungal cells can absorb this light energy and transform it into heat to damage the cell wall, resulting in fungal apoptosis [24, 25]. The laser also increases the temperature (to approximately 40°C) of the nail plate at the treatment site [16]. The fungi are damaged by repeated heat stimulation and the fungal mitochondria produce excess reactive oxygen species that overwhelm the protective capacity of the fungal cells, resulting in cell/fungal apoptosis and even death. The main advantage of antifungal agents is the maintenance of the effect even after the end of treatment. On the other hand, systemic drugs are sometimes contraindicated in some patients (e.g., those with liver dysfunction), while topical drugs are associated with a compliance issue [26]. Lasers could be used as an alternative in those cases and in patients who do not want to take medicine. In addition, combination treatments (laser and drugs) should be explored in the future.

Regarding the satisfaction survey, only four (12.1%) out of 33 people were very satisfied and six (18.2%) were satisfied.
This study has limitations. A mycology assessment was not conducted and the follow-up was relatively short.

5. Conclusions

The 1064-nm Nd-YAG laser has clinical benefits against onychomycosis, without any side effect. Higher numbers of treatments provide better benefits at 24 weeks, but the number of treatments had no impact on the short-term outcomes (8 and 16 weeks). The efficacy of laser treatment on degree II onychomycosis was better than for degree III. SCIO may be used for planning treatment.
Table 4: Efficacy rates according to severity of onychomycosis in each group at different time points.

| Group | Cases, n | Week 8 | Week 16 | Week 24 |
|-------|----------|--------|---------|---------|
| Group A | | | | |
| II | 75 | 47 (62.7%) | 53 (70.7%) | 54 (72.0%) |
| III | 80 | 8 (10.0%) | 7 (8.8%) | 4 (5.0%) |
| p | <0.001 | <0.001 | <0.001 |
| Group B | | | | |
| II | 88 | 46 (52.3%) | 62 (70.5%) | 58 (65.9%) |
| III | 87 | 9 (10.3%) | 11 (12.6%) | 19 (21.8%) |
| p | <0.001 | <0.001 | <0.001 |
| Group C | | | | |
| II | 57 | 28 (49.1%) | 37 (64.9%) | 41 (71.9%) |
| III | 55 | 3 (5.5%) | 19 (34.6%) | 21 (38.2%) |
| p | <0.001 | 0.001 | <0.001 |

Group A: four sessions; Group B: eight sessions; Group C: 12 sessions. The clinical efficacy rate was defined as the total percentage of nails with complete response and significant response. “Complete response or cure” was defined as fully normal appearing nail measured from the proximal nail fold to involved nail; “significant response” was defined as >60% normal-appearing nail compared with the area of the initially infected nail; “moderate response” was defined as 20–60% normal-appearing nail; and “no response” was defined as <20% normal-appearing nail.

Table 5: Univariable and multivariable logistic regression analysis for efficacy rate at 24 weeks.

| Variable | Univariable logistic regression | Multivariable logistic regression |
|----------|---------------------------------|----------------------------------|
|          | OR (95%CI)                      | p      | OR (95%CI)                      | p      |
| Treatment group |                                  |        |                                  |        |
| Group A   | Reference                       |        |                                  |        |
| Group B   | 1.314 (0.845, 2.043)            | 0.225  | 1.009 (0.564, 1.805)             | 0.976  |
| Group C   | 2.074 (1.265, 3.401)            | 0.004  | 2.589 (1.342, 4.994)             | 0.005  |
| Age (years) | 0.919 (0.896, 0.941)            | <0.001 | 0.900 (0.870, 0.931)             | <0.001 |
| Duration of disease (years) | 0.789 (0.671, 0.927)            | 0.004  | 1.114 (0.883, 1.406)             | 0.363  |
| Gender |                                  |        |                                  |        |
| Male | Reference                       |        |                                  |        |
| Female | 1.320 (0.882, 1.974)            | 0.177  |                                  |        |
| Nail thickness (mm) |                                  |        |                                  |        |
| <1 | Reference                       |        |                                  |        |
| 1–2 | 0.075 (0.030, 0.191)            | <0.001 | 0.24 (0.079, 0.734)              | 0.012  |
| Mean laser energy (J/cm²) | 0.979 (0.967, 0.992)            | 0.001  | 0.998 (0.981, 1.015)             | 0.836  |
| Location of infected nails |                                  |        |                                  |        |
| Fingernail | Reference                       |        |                                  |        |
| Toenail | 1.285 (0.765, 2.157)            | 0.343  |                                  |        |
| Severity of infected nails |                                  |        |                                  |        |
| II | Reference                       |        |                                  |        |
| III | 0.108 (0.070, 0.168)            | <0.001 | 0.107 (0.052, 0.219)             | <0.001 |
| Clinical type of onychomycosis |                                  |        |                                  |        |
| DLSO | Reference                       |        |                                  |        |
| WSO  | 0.644 (0.348, 1.190)            | 0.160  | 0.968 (0.441, 2.127)             | 0.936  |
| PSO  | 0.187 (0.053, 0.659)            | 0.009  | 0.575 (0.124, 2.674)             | 0.480  |
| TDO  | 0.367 (0.217, 0.621)            | <0.001 | 1.304 (0.576, 2.955)             | 0.525  |

Group A: four sessions; Group B: eight sessions; Group C: 12 sessions. OR: odds ratio; CI: confidence interval; DLSO: distal lateral subnail onychomycosis; WSO: white superficial onychomycosis; PSO: proximal subnail onychomycosis; TDO: total dystrophy onychomycosis.
Table 6: Satisfaction survey.

|                | Group A (N = 33) | Group B (N = 39) | Group C (N = 30) | P     |
|----------------|-----------------|-----------------|-----------------|-------|
| Very satisfied | 4 (12.1%)       | 8 (20.5%)       | 10 (30.3%)      |       |
| Satisfied      | 6 (18.2%)       | 19 (48.7%)      | 5 (16.7%)       | 0.010 |
| Slightly satisfied    | 16 (48.5%)  | 7 (18.0%)       | 10 (30.3%)      |       |
| Not satisfied    | 7 (21.2%)       | 5 (12.8%)       | 5 (16.7%)       |       |

Group A: four sessions; Group B: eight sessions; Group C: 12 sessions. Group A vs. Group B, P = 0.025; Group A vs. Group C, P = 0.240; Group B vs. Group C, P = 0.065.

Data Availability

The datasets generated and analyzed during the present study are available from the corresponding author on reasonable request.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by Ethics Committee. Written informed was obtained from patients/parents/guardians.

Consent

Informed consent was obtained from all individual participants included in the study.

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

[1] M. Ameen, J. T. Lear, V. Madan, M. F. Mohd Mustapa, and M. Richardson, "British Association of Dermatologists' guidelines for the management of onychomycosis 2014," British Journal of Dermatology, vol. 171, no. 5, pp. 937–958, 2014.
[2] S. Eisman and R. Sinclair, "Fungal nail infection: diagnosis and management," BMJ, vol. 348, no. mar24 3, pp. g1800–g1800, 2014.
[3] B. S. Schlefan, "Onychomycosis: a compendium of facts and a clinical experience," The Journal of Foot and Ankle Surgery, vol. 38, no. 4, pp. 290–302, 1999.
[4] J. Yu and R. Y. Li, "Epidemiological investigation of onychomycosis in China," Chinese Journal Mycology, vol. 1, pp. 63–64, 2006.
[5] K. Kalokasidis, M. Onder, M.-G. Trakatelli, B. Richert, and K. Fritz, "The effect of Q-switched Nd:YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo," Dermatology Research and Practice, vol. 2013, Article ID 379725, 10 pages, 2013.
[6] D. P. Westerberg and M. J. Voyack, "Onychomycosis: current trends in diagnosis and treatment," American Family Physician, vol. 88, no. 11, pp. 762–770, 2013.
[7] A. E. Ortiz, M. M. Avram, and M. A. Wanner, "A review of lasers and light for the treatment of onychomycosis," Lasers in Surgery and Medicine, vol. 46, no. 2, pp. 117–124, 2014.
[8] A. K. Gupta, E. A. Cooper, and M. Paquet, "Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with monoo- and combined therapy of terbinafine and itraconazole," Journal of Cutaneous Medicine and Surgery, vol. 17, no. 3, pp. 201–206, 2013.
[9] A. Shemer, "Update: medical treatment of onychomycosis," Dermatologic Therapy, vol. 25, no. 6, pp. 582–593, 2012.
[10] D. C. de Sa, A. P. Lamas, and A. Tosti, "Oral therapy for onychomycosis: an evidence-based review," American Journal of Clinical Dermatology, vol. 15, no. 1, pp. 17–36, 2014.
[11] A. K. Bhatta, X. Huang, U. Keyal, and J. J. Zhao, "Laser treatment for onychomycosis: a review," Mycoses, vol. 57, no. 12, pp. 734–740, 2014.
[12] M. Borovoy and M. Tracy, "Noninvasive CO2 laser fenestration improves treatment of onychomycosis," Clinical Laser Monthly, vol. 10, no. 8, pp. 123–124, 1992.
[13] E. H. Lim, H. R. Kim, Y. O. Park et al., "Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream," Journal of the American Academy of Dermatology, vol. 70, no. 5, pp. 918–923, 2014.
[14] B. R. Zhou, Y. Lu, F. Permatasari et al., "The efficacy of fractional carbon dioxide (CO2) laser combined with luliconazole 1% cream for the treatment of onychomycosis: a randomized, controlled trial," Medicine (Baltimore), vol. 95, no. 44, p. e5141, 2016.
[15] A. K. Bhatta, U. Keyal, X. Huang, and J. J. Zhao, "Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis," Journal of the American Academy of Dermatology, vol. 74, no. 5, pp. 916–923, 2016.
[16] A. S. Landsman and A. H. Robbins, "Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure: some follow-up observations at 270 days," Journal of the American Podiatric Medical Association, vol. 102, no. 2, pp. 169–171, 2012.
[17] R. N. Zhang, D. K. Wang, F. L. Zhuo, X. H. Duan, X. Y. Zhang, and J. J. Zhao, "Long-pulse Nd:YAG 1064-nm laser treatment for onychomycosis," Chinese Medical Journal (England), vol. 125, pp. 3288–3291, 2012.
[18] H. J. Kim, H. J. Park, D. H. Suh et al., "Clinical factors influencing outcomes of 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser treatment for onychomycosis," Annals of Dermatology, vol. 30, no. 4, pp. 493–495, 2018.
[19] R. Wanitphakdeedecha, K. Thanomkitti, S. Bunyaratavej, and W. Manuskiatti, "Efficacy and safety of 1064-nm Nd:YAG laser in treatment of onychomycosis," Journal of Dermatological Treatment, vol. 27, no. 1, pp. 75–79, 2016.
[20] A. Zalacain, A. Merlos, E. Planell, E. G. Cantadori, T. Vinuesa, and M. Vinas, "Clinical laser treatment of toenail onychomycoses," Lasers in Medical Science, vol. 33, no. 4, pp. 927–933, 2018.
[21] A. Y. Sergeev, A. K. Gupta, and Y. V. Sergeev, "The Scoring Clinical Index for Onychomycosis (SCIO index)," Skin Therapy Letter, vol. 7, no. Suppl 1, pp. 6–7, 2002.
evaluated with scoring clinical index,” *Chinese Journal of Dermatology*, vol. 38, no. 8, pp. 470–473, 2005.

[23] A. Y. Finlay, “Pharmacokinetics of terbinafine in the nail,” *British Journal of Dermatology*, vol. 126, no. s39, pp. 28–32, 1992.

[24] S. A. Ghavam, S. Aref, E. Mohajerani, M. R. Shidfar, and H. Moravvej, “Laser irradiation on growth of trichophyton rubrum: an in vitro study,” *Journal of Lasers in Medical Sciences*, vol. 6, no. 1, pp. 10–16, 2015.

[25] Z. L. Xu, J. Xu, F. L. Zhuo et al., “Effects of laser irradiation on Trichophyton rubrum growth and ultrastructure,” *Chinese Medical Journal (England)*, vol. 125, no. 20, pp. 3697–3700, 2012.

[26] I. R. Bristow, “The effectiveness of lasers in the treatment of onychomycosis: a systematic review,” *Journal of Foot and Ankle Research*, vol. 7, no. 1, 2014.